Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis

International Urology and Nephrology

Volumn 43, Issue 2, 2011, Pages 491-498

  Rysz, Jacek ^a   Banach, Maciej ^a   Stolarek, Robert A ^a   Mikhailidis, Dimitri P ^b   Cialkowska Rysz, Aleksandra ^a   Pokoca, Lech ^a   Piechota, Mariusz ^a   Baj, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Chronic kidney disease; Hemodialysis; Metalloproteinase MMP 2; MMP 9; TIMP 2; Tissue inhibitors TIMP 1

Indexed keywords

C REACTIVE PROTEIN; GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HUMAN; MALE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 79959722589     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-009-9683-1     Document Type: Article

References (21)

1. Lelongt B, Legallicier B, Piedagnel R, Ronco PM (2001) Do matrix metalloproteinasesMMP-2 and MMP-9 (gelatinases) play a role in renal development, physiology and glomerular diseases? Curr Opin Nephrol Hypertens 10:7-12
2. Zeisberg M, Maeshima Y, Mosterman B, Kalluri R (2002) Renal fibrosis. Extracellular matrix microenvironment regulates migratory behavior of activated tubular epithelial cells. Am J Pathol 6:2001-2008 (Pubitemid 34663393)
3. Cheng S, Lovett DH (2003) Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am J Pathol 6:1937-1949 (Pubitemid 36613051)
4. Akahane T, Akahane M, Shah A, Thorgeirsson UP (2004) TIMP-1 stimulates proliferation of human aortic smooth muscle cells and Ras effector pathways. Biochem Biophys Res Commun 1:440-445 (Pubitemid 39311514)
5. Han X, Sun Y, Scott S, Bleich D (2001) Tissue inhibitor of metalloproteinase-1 prevents cytokine-mediated dysfunction and cytotoxicity in pancreatic islets and beta-cells. Diabetes 50:1047-1055 (Pubitemid 32374535)
6. Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 32:S112-S119 (Pubitemid 28527268)
7. Hansson GK (2005) Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 352:1685-1695
8. Preston GA, Barrett CV, Alcorta DA et al (2002) Serum matrix metalloproteinases MMP-2 and MMP-3 levels in dialysis patients vary independently of CRP and IL-6 levels. Nephron 92:817-823 (Pubitemid 36151362)
9. Arenas MD, Alvarez-Ude F, GilMTet al (2006) Application of NKF-K/DOQI clinical practice guidelines for bone metabolism and disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units. Nephrol Dial Transplant 21:1663-1668 (Pubitemid 43834646)
10. Chou FP, Chu SC, Cheng MC et al (2002) Effect of hemodialysis on the plasma level of type IV collagenases and their inhibitors. Clin Biochem 35:383-388
11. Chang HR, Yang SF, Li ML, Lin CC, Hsieh YS, Lian JD (2006) Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease. Clin Chim Acta 366:243-248
12. Deschamps AM, Yarbrough WM, Squires CE et al (2005) Trafficking of the membrane type-1 matrix metalloproteinase in ischemia and reperfusion: relation to interstitial membrane type-1 matrix metalloproteinase activity. Circulation 111:1166-1174 (Pubitemid 40365479)
13. Pawlak K, Pawlak D, Mysliwiec M (2007) Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients. Am J Nephrol 27:221-225 (Pubitemid 47164669)
14. Rysz J, Stolarek R, Banach M et al (2006) TNF-alfa priming effect on polymorphonuclear leukocytes reactive oxygen species generation and adhesion molecule expression in hemodialyzed patients. Arch Immunol Ther Exp 54:209-215 (Pubitemid 44257342)
15. Pourfarziani V, Einollahi B, Assari S et al (2007) A link between the outcome of living unrelated kidney transplantation and HLA compatibility: a preliminary rsrt. Arch Med Sci 3:108-111 (Pubitemid 47237974)
16. Rysz J, Majewska E, Stolarek RA, Banach M, Cialkowska-Rysz A, Baj Z (2006) The increased levels of soluble TNFa receptors and cellular adhesion molecules in patients undergoing bioincompatible hemodialysis. Am J Nephrol 26:437-444 (Pubitemid 44971734)
17. Barylski M, Banach M, Mikhailidis DP, Pawlicki L, Kowalski J (2008) Decreased kidney function as a risk factor for cardiovascular events in subjects with metabolic syndrome - a pilot study. Arch Med Sci 4:417-423
18. Rysz J, Banach M, Stolarek RA et al (2007) Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy. J Nephrol 20:444-452 (Pubitemid 350081499)
19. Pawlak K, Pawlak D, Mysliwiec M (2007) Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients. Atherosclerosis 190:199-204 (Pubitemid 44908316)
20. Rysz J, Banach M, Ciałkowska-Rysz A, Stolarek R, Drozdz J, Okoński P (2006) Blood serum levels of IL-2, IL-6, IL-8, TNF-a and IL-1b in patients on maintenance hemodialysis. Cell Mol Immunol 3:151-154
21. Rysz J, Aronow WS, Stolarek RS, Hannam S, Mikhailidis DP, Banach M (2009) Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets. 13:541-550